Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock Up Expiration Hell Portfolio: Wave II -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (105)	9/27/2005 9:30:41 PM
From: tuck	Respond to of 107

Sunesis stumbles out the Wave III window: >>[Archiving from Briefing] 09:47 ET Sunesis Pharma IPO prices below range (SNSS) 7.00 :Sunesis Pharmaceuticals prices its IPO at $7, below its expected range of $9-11. Sunesis is a clinical-stage biopharmaceutical co. The co is advancing three proprietary oncology product candidates through in-house R&D efforts. All three are inhibitors of the cell division process, known as cell-cycle inhibitors, intended for the treatment of cancer. Its lead product candidate, SNS-595, is a novel cytotoxic. The co is conducting two Phase I clinical trials with SNS-595, and expects an additional Phase I clinical trial in certain leukemias this month. Its second most advanced product candidate, SNS-032, is a CDK inhibitor. The co has five strategic collaborations with Biogen Idec, JNJ, and Merck (MRK)... Note: The pricing here shows a trend over the past few months of a lack of interest for biotech IPOs. The Biotech Index (BTK) shows that biotechs have been doing well, just not the early clinical stage ones. However, the new FDA chief is the former head of the National Cancer Institute, so cos focusing on cancer, such as Sunesis, should not be totally forgotten by traders, especially given its collaboration deals with major drugmakers. This is a 6 mln share deal led by Lehman.<< Thanks to Ian for the dig. Cheers, Tuck